Covered recipient · General Payments record
LISA B CONNERY
Allopathic & Osteopathic Physicians Family Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$18,360.32
113 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Travel and Lodging | $14,200.59 | 40 |
| Consulting Fee | $2,100.00 | 1 |
| Food and Beverage | $1,934.19 | 69 |
| Education | $125.54 | 3 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Eli Lilly and Company | $16,369.46 | 55 |
| Boehringer Ingelheim International GmbH | $1,199.44 | 11 |
| AbbVie Inc. | $197.82 | 14 |
| Astellas Pharma US Inc | $99.79 | 3 |
| Lilly USA, LLC | $77.18 | 7 |
| Novo Nordisk Inc | $64.54 | 2 |
| IDORSIA PHARMACEUTICALS US INC | $50.74 | 3 |
| GlaxoSmithKline, LLC. | $42.60 | 3 |
| Dexcom, Inc. | $32.98 | 2 |
| PFIZER INC. | $32.43 | 2 |
| AstraZeneca Pharmaceuticals LP | $29.26 | 2 |
| Corcept Therapeutics | $22.96 | 1 |
| Axsome Therapeutics, Inc. | $22.56 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $20.60 | 1 |
| Ultragenyx Pharmaceutical Inc. | $18.81 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $17.00 | 1 |
| Azurity Pharmaceuticals, Inc. | $16.98 | 1 |
| Kowa Pharmaceuticals America, Inc. | $16.39 | 1 |
| Exact Sciences Corporation | $15.51 | 1 |
| Amgen Inc. | $13.27 | 1 |
Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
LISA B CONNERY
NPI 1205828977 · CMS profile ID 9503
Allopathic & Osteopathic Physicians / Family Medicine
NORMAN, OK
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1205828977?year=2023&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- LISA B CONNERY, NPI 1205828977, CMS profile ID 9503. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1205828977?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). LISA B CONNERY, NPI 1205828977, CMS profile ID 9503. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1205828977?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- LISA B CONNERY, NPI 1205828977, CMS profile ID 9503, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1205828977?year=2023&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
113 matching records · $18,360.32 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–113 of 113.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Eli Lilly and Company | $18.08 | 03/06/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031880877 | CMS |
| Eli Lilly and Company | $3.98 | 03/06/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031880881 | CMS |
| Eli Lilly and Company | $3.98 | 03/06/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031880885 | CMS |
| Eli Lilly and Company | $139.36 | 03/06/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031880891 | CMS |
| Eli Lilly and Company | $475.00 | 03/06/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031880897 | CMS |
| Eli Lilly and Company | $24.99 | 03/06/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031906243 | CMS |
| Eli Lilly and Company | $13.93 | 03/06/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031906247 | CMS |
| Eli Lilly and Company | $199.00 | 03/06/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031906251 | CMS |
| AbbVie Inc. | $19.83 | 01/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 996503011 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.82 | 01/19/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015002301 | CMS |
| IDORSIA PHARMACEUTICALS US INC | $17.03 | 01/19/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1034299237 | CMS |
| Lilly USA, LLC | $9.23 | 01/17/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031856385 | CMS |
| Exact Sciences Corporation | $15.51 | 01/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1026646443 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $2,947,402.59 | 237 |
| PY2024 | Recipient | $38,645.81 | 22 |
| PY2024 | Principal investigator | $3,031,009.48 | 70 |
| PY2023 | Recipient | $649.72 | 3 |
| PY2023 | Principal investigator | $2,692,454.09 | 131 |
| PY2022 | Recipient | $26,997.21 | 15 |
| PY2022 | Principal investigator | $1,957,706.53 | 125 |
| PY2021 | Principal investigator | $2,228,001.31 | 608 |
| PY2020 | Recipient | $12,692.04 | 9 |
| PY2020 | Principal investigator | $1,474,593.52 | 211 |
| PY2019 | Recipient | $22,840.16 | 19 |
| PY2019 | Principal investigator | $1,166,870.19 | 166 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
237 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,795.80 | 12/19/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184278924 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $210.00 | 12/15/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798475 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $29,877.26 | 12/15/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798477 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,797.50 | 12/15/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798479 |
| Principal investigator 1 | PFIZER INC. | $1,287.00 | 12/15/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228728545 |
| Principal investigator 1 | PFIZER INC. | $1,287.00 | 12/15/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228729156 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7,200.00 | 12/10/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798473 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $5,959.00 | 12/04/2025 | Non-covered Recipient Entity THE ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | No dispute reported | 06/30/2026 | 1211663884 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $12,988.00 | 12/03/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH | A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event | No dispute reported | 06/30/2026 | 1185552271 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $86.00 | 12/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658560 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 12/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658562 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $49.88 | 12/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658564 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658566 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658568 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658570 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658572 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658574 |
| Principal investigator 1 | Genentech, Inc. | $1,800.00 | 11/26/2025 | Non-covered Recipient Entity THE ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211663808 |
| Principal investigator 1 | PFIZER INC. | $704.90 | 11/26/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228727967 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $19,247.00 | 11/20/2025 | Non-covered Recipient Entity THE ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | No dispute reported | 06/30/2026 | 1211663862 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $511.00 | 11/19/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658580 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.36 | 11/19/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658582 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $9,213.00 | 11/14/2025 | Non-covered Recipient Entity THE ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | No dispute reported | 06/30/2026 | 1211663871 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $21,655.20 | 11/14/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184261243 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $688.80 | 11/14/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184261295 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $57.00 | 11/14/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184261297 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $83.00 | 11/14/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184261299 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $108.00 | 11/07/2025 | Non-covered Recipient Entity THE ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | No dispute reported | 06/30/2026 | 1211663856 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $8,499.00 | 11/07/2025 | Non-covered Recipient Entity THE ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | No dispute reported | 06/30/2026 | 1211663865 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,349.40 | 11/07/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258875 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,349.40 | 11/07/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258877 |
| Principal investigator 1 | PFIZER INC. | $12,250.00 | 11/04/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research LLC | A PHASE 3 STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS 60 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228707523 |
| Principal investigator 1 | PFIZER INC. | $9,607.15 | 11/04/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228738180 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 11/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658548 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658550 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658552 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658554 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658556 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658558 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $28,376.88 | 10/29/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798471 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $146.00 | 10/27/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658576 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6.96 | 10/27/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658578 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,103.00 | 10/23/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184252460 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $17,369.80 | 10/16/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184250471 |
| Principal investigator 1 | Eli Lilly and Company | $3,486.99 | 10/14/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLS | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY OF LY3549492 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS 55 TO 80 YEARS OF AGE AND BMI WITHIN 22 TO 25 KG/M2 | No dispute reported | 06/30/2026 | 1187874509 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,820.80 | 10/03/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184244499 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,717.80 | 10/03/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184244515 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 10/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658536 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658538 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658540 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658542 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658544 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658546 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 09/24/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658534 |
| Principal investigator 1 | PFIZER INC. | $20,984.53 | 09/24/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228752975 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $420.00 | 09/23/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798467 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,595.00 | 09/23/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798469 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $269.00 | 09/19/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220795149 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,922.40 | 09/18/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184240800 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $56,467.60 | 09/10/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184235841 |
| Principal investigator 1 | PFIZER INC. | $6,660.15 | 09/09/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228753524 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $29,335.32 | 09/03/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798465 |
| Principal investigator 1 | Lexicon Pharmaceuticals, Inc. | $3,900.00 | 09/03/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | LX9211.1-204-DPN | No dispute reported | 06/30/2026 | 1248067387 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,920.10 | 09/03/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184234989 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658500 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658502 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658504 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658506 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658508 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 09/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658526 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $210.00 | 08/28/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798459 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $315.00 | 08/28/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798461 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $525.00 | 08/28/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798463 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $16,330.00 | 08/26/2025 | Non-covered Recipient Entity THE ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | No dispute reported | 06/30/2026 | 1211663820 |
| Principal investigator 1 | PFIZER INC. | $12,714.45 | 08/26/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228719771 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,675.80 | 08/26/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184230677 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,675.80 | 08/26/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184230679 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $587.30 | 08/26/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184230681 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,813.00 | 08/26/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184230683 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $151.20 | 08/26/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184230685 |
| Principal investigator 1 | AstraZeneca UK Limited | $9,915.60 | 08/13/2025 | Non-covered Recipient Entity ALABAMA KIDNEY RESEARCH | Phase 2b Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety, and Tolerability of AZD2373 in Participants with APOL1-Mediated Kidney Disease (APPRECIATE) | No dispute reported | 06/30/2026 | 1185552269 |
| Principal investigator 1 | PFIZER INC. | $271.80 | 08/08/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS 60 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228707343 |
| Principal investigator 1 | PFIZER INC. | $131.75 | 08/08/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS 60 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228707525 |
| Principal investigator 1 | PFIZER INC. | $757.50 | 08/08/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS 60 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228707598 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $40,629.82 | 08/06/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798457 |
| Principal investigator 1 | PFIZER INC. | $24,607.10 | 08/05/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228768367 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658488 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658490 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658492 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658494 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658496 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658498 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.79 | 08/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658520 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 08/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658524 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $210.00 | 07/30/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798455 |
| Principal investigator 1 | Amgen Inc. | $25,092.23 | 07/28/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH | A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a) | No dispute reported | 06/30/2026 | 1246639007 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $292.00 | 07/28/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658528 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $10.00 | 07/28/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658530 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $13.92 | 07/28/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658532 |
| Principal investigator 1 | PFIZER INC. | $3,412.80 | 07/22/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS 60 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228707345 |
| Principal investigator 1 | PFIZER INC. | $550.00 | 07/18/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228762669 |
| Principal investigator 1 | AstraZeneca UK Limited | $73,150.00 | 07/16/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH | A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD6234 Co administered with a GLP 1 Receptor Agonist in Participants with Type 2 Diabetes and Overweight or Obesity | No dispute reported | 06/30/2026 | 1185552273 |
| Principal investigator 1 | PFIZER INC. | $34,780.52 | 07/15/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228788384 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $174.00 | 07/09/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798451 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $630.00 | 07/09/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798453 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,174.60 | 07/04/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184212723 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658510 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658512 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658514 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658516 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658518 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 07/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658522 |
| Principal investigator 1 | PFIZER INC. | $42,339.99 | 06/26/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228775857 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $42,959.28 | 06/25/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798449 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $116.60 | 06/24/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658482 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $401.50 | 06/24/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658484 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $15.66 | 06/24/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658486 |
| Principal investigator 1 | Amgen Inc. | $27,626.20 | 06/23/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity | No dispute reported | 06/30/2026 | 1246639061 |
| Principal investigator 1 | Eli Lilly and Company | $411.00 | 06/23/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLS | A PHASE 3, MULTICENTER, RANDOMIZED, PARALLEL-DESIGN, OPEN-LABEL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 COMPARED WITH INSULIN DEGLUDEC IN PARTICIPANTS WITH TYPE 2 DIABETES CURRENTLY TREATED WITH BASAL INSULIN (QWINT-3) | No dispute reported | 06/30/2026 | 1187872559 |
| Principal investigator 1 | Eli Lilly and Company | $419.00 | 06/23/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLS | EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | No dispute reported | 06/30/2026 | 1187874499 |
| Principal investigator 1 | Eli Lilly and Company | $645.00 | 06/23/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLS | A STUDY OF TIRZEPATIDE (LY3298176) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES SWITCHING FROM DULAGLUTIDE (SURPASS-SWITCH) (SURPASS-SWITCH) | No dispute reported | 06/30/2026 | 1187874501 |
| Principal investigator 1 | Eli Lilly and Company | $14,309.00 | 06/23/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLS | A PHASE 3B, RANDOMIZED CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TIRZEPATIDE COMPARED TO SEMAGLUTIDE 2.4 MG IN ADULTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES (SURMOUNT-5) | No dispute reported | 06/30/2026 | 1187875835 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,400.00 | 06/12/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184206191 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $5,210.00 | 06/11/2025 | Non-covered Recipient Entity THE ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211663758 |
| Principal investigator 1 | Eli Lilly and Company | $133,442.00 | 06/10/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLS | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY COMPARED TO PLACEBO IN ADULT PARTICIPANTS WITH TYPE 1 DIABETES AND OBESITY OR OVERWEIGHT (SURPASS-T1D-1) | No dispute reported | 06/30/2026 | 1187875197 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,400.00 | 06/05/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184204127 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 06/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658462 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658464 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658466 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658468 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658470 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658472 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $182.50 | 05/27/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658480 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,410.00 | 05/27/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798445 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7,944.40 | 05/27/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798447 |
| Principal investigator 1 | Eli Lilly and Company | $33,896.00 | 05/27/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLS | A PARALLEL-GROUP TREATMENT, PHASE 2, DOUBLE-BLIND STUDY OF ONCE-WEEKLY SUBCUTANEOUS LY3457263 COMPARED TO PLACEBO IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS ON A STABLE DOSE OF TIRZEPATIDE OR SEMAGLUTIDE WHO FAILED TO ACHIEVE HBA1C GOAL | No dispute reported | 06/30/2026 | 1187875205 |
| Principal investigator 1 | Eli Lilly and Company | $369.50 | 05/27/2025 | Non-covered Recipient Entity INTEND RESEARCH LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1187881632 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,500.00 | 05/22/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184197547 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,883.00 | 05/22/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184197549 |
| Principal investigator 1 | PFIZER INC. | $34,803.44 | 05/14/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228771546 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $19,740.14 | 05/09/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798443 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,883.00 | 05/08/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184193723 |
| Principal investigator 1 | PFIZER INC. | $10,327.52 | 05/06/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228774201 |
| Principal investigator 1 | Eli Lilly and Company | $6,837.00 | 05/05/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLS | A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 ADMINISTERED WEEKLY USING A FIXED DOSE ESCALATION COMPARED TO INSULIN GLARGINE IN INSULIN-NAIVE ADULTS WITH TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 1187876295 |
| Principal investigator 1 | PFIZER INC. | $23,413.39 | 05/03/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228762788 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $49.88 | 05/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658442 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $49.88 | 05/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658444 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 05/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658446 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $86.00 | 05/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658448 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $86.00 | 05/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658450 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658452 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658454 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658456 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658458 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658460 |
| Principal investigator 1 | Eli Lilly and Company | $240.00 | 04/30/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLS | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY COMPARED TO PLACEBO IN ADULT PARTICIPANTS WITH TYPE 1 DIABETES AND OBESITY OR OVERWEIGHT (SURPASS-T1D-1) | No dispute reported | 06/30/2026 | 1187872561 |
| Principal investigator 1 | Eli Lilly and Company | $165.00 | 04/30/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLS | A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH SEMAGLUTIDE ONCE WEEKLY IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN WITH OR WITHOUT SGLT2 INHIBITOR (TRANSCEND-T2D-2) | No dispute reported | 06/30/2026 | 1187874503 |
| Principal investigator 1 | Eli Lilly and Company | $165.00 | 04/30/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLS | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL ORFORGLIPRON COMPARED WITH DAPAGLIFLOZIN IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-2) | No dispute reported | 06/30/2026 | 1187875841 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $12,336.80 | 04/28/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184190791 |
| Principal investigator 1 | Amgen Inc. | $4,729.00 | 04/24/2025 | Non-covered Recipient Entity INTEND RESEARCH, LLC | A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke | No dispute reported | 06/30/2026 | 1246642830 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $116.60 | 04/23/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658474 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,299.50 | 04/23/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658476 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $74.82 | 04/23/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658478 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $295.40 | 04/23/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184189119 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $159.60 | 04/23/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184189129 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,206.80 | 04/23/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184189131 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $71.40 | 04/23/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184189135 |
| Principal investigator 1 | Eli Lilly Export S.A. Puerto Rico Branch | $4,652.82 | 04/17/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLS | A PARALLEL-GROUP TREATMENT, PHASE 2, DOUBLE-BLIND STUDY OF ONCE-WEEKLY SUBCUTANEOUS LY3457263 COMPARED TO PLACEBO IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS ON A STABLE DOSE OF TIRZEPATIDE OR SEMAGLUTIDE WHO FAILED TO ACHIEVE HBA1C GOAL | No dispute reported | 06/30/2026 | 1187875211 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,314.40 | 04/15/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184183440 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $46,886.14 | 04/11/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798441 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658430 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658432 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658434 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658436 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658438 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 04/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658440 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,552.80 | 03/19/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184174602 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $23,924.74 | 03/18/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798439 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658390 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658392 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658394 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658396 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658398 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $49.88 | 03/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658400 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $86.00 | 03/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658402 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 03/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658404 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $399.60 | 02/25/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658416 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $438.00 | 02/25/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658418 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $12.18 | 02/25/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658420 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.20 | 02/25/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658422 |
| Principal investigator 1 | Eli Lilly and Company | $16,028.38 | 02/25/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLS | A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (ACHIEVE-1) | No dispute reported | 06/30/2026 | 1187875199 |
| Principal investigator 1 | Eli Lilly and Company | $256.52 | 02/25/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLS | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1187876291 |
| Principal investigator 1 | Eli Lilly and Company | $1,308.65 | 02/25/2025 | Non-covered Recipient Entity INTEND RESEARCH LLC | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | No dispute reported | 06/30/2026 | 1187882084 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $15,500.00 | 02/25/2025 | Non-covered Recipient Entity THE ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211663754 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,406.80 | 02/18/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184154170 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658378 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658380 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658382 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658384 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658386 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 02/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658388 |
| Principal investigator 1 | Eli Lilly and Company | $570.00 | 01/31/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLS | A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT RELATED COMORBIDITIES (ATTAIN-1) | No dispute reported | 06/30/2026 | 1187872555 |
| Principal investigator 1 | Eli Lilly and Company | $260.00 | 01/31/2025 | Non-covered Recipient Entity INTEND RESEARCH LLC | A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (ACHIEVE-1) | No dispute reported | 06/30/2026 | 1187882172 |
| Principal investigator 1 | Eli Lilly and Company | $887.97 | 01/31/2025 | Non-covered Recipient Entity INTEND RESEARCH LLC | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) | No dispute reported | 06/30/2026 | 1187882882 |
| Principal investigator 1 | Eli Lilly and Company | $405.00 | 01/31/2025 | Non-covered Recipient Entity INTEND RESEARCH LLC | A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH SEMAGLUTIDE ONCE WEEKLY IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN WITH OR WITHOUT SGLT2 INHIBITOR (TRANSCEND-T2D-2) | No dispute reported | 06/30/2026 | 1187883564 |
| Principal investigator 1 | Eli Lilly and Company | $405.00 | 01/31/2025 | Non-covered Recipient Entity INTEND RESEARCH LLC | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL ORFORGLIPRON COMPARED WITH DAPAGLIFLOZIN IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-2) | No dispute reported | 06/30/2026 | 1187883864 |
| Principal investigator 1 | Amgen Inc. | $6,284.00 | 01/30/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH | A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke | No dispute reported | 06/30/2026 | 1246639017 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,068.40 | 01/29/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184149844 |
| Principal investigator 1 | Amgen Inc. | $413,453.96 | 01/27/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | No dispute reported | 06/30/2026 | 1246639047 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $233.20 | 01/27/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658406 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $693.50 | 01/27/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658408 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.24 | 01/27/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658410 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.16 | 01/27/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658412 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $8.70 | 01/27/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658414 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $45,060.40 | 01/27/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798437 |
| Principal investigator 1 | Eli Lilly and Company | $328.67 | 01/27/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLS | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) | No dispute reported | 06/30/2026 | 1187876531 |
| Principal investigator 1 | Amgen Inc. | $69,000.06 | 01/22/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH | A Study to Evaluate the Efficacy, Safety & Tolerability of Maridebart Cafraglutide in Adults With T2DM | No dispute reported | 06/30/2026 | 1246639071 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,012.00 | 01/21/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184149042 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20,580.98 | 01/17/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798435 |
| Principal investigator 1 | Eli Lilly and Company | $46,897.00 | 01/07/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLS | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) | No dispute reported | 06/30/2026 | 1187871547 |
| Principal investigator 1 | Eli Lilly and Company | $41,085.00 | 01/07/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLS | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1187874487 |
| Principal investigator 1 | Eli Lilly and Company | $80,870.00 | 01/07/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLS | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | No dispute reported | 06/30/2026 | 1187875193 |
| Principal investigator 1 | Eli Lilly and Company | $390,126.00 | 01/07/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLS | A STUDY OF ORFORGLIPRON FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES (ATTAIN-MAINTAIN) | No dispute reported | 06/30/2026 | 1187875195 |
| Principal investigator 1 | Eli Lilly and Company | $144,026.00 | 01/07/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLS | A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT RELATED COMORBIDITIES (ATTAIN-1) | No dispute reported | 06/30/2026 | 1187875959 |
| Principal investigator 1 | Eli Lilly and Company | $28,682.00 | 01/07/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLS | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | No dispute reported | 06/30/2026 | 1187876281 |
| Principal investigator 1 | Eli Lilly and Company | $158,087.00 | 01/07/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLS | A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH SEMAGLUTIDE ONCE WEEKLY IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN WITH OR WITHOUT SGLT2 INHIBITOR (TRANSCEND-T2D-2) | No dispute reported | 06/30/2026 | 1187876283 |
| Principal investigator 1 | Eli Lilly and Company | $296,994.00 | 01/07/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLS | A STUDY OF LY3298176 (TIRZEPATIDE) FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES | No dispute reported | 06/30/2026 | 1187876307 |
| Principal investigator 1 | Eli Lilly and Company | $20,825.00 | 01/07/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLS | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL ORFORGLIPRON COMPARED WITH DAPAGLIFLOZIN IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-2) | No dispute reported | 06/30/2026 | 1187876309 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,490.60 | 01/07/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184145774 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658368 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658370 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658372 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658374 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658376 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $86.00 | 01/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658424 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 01/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658426 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $49.88 | 01/01/2025 | Non-covered Recipient Entity Amr Norman | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658428 |